Interim Management Statement

Dechra Pharmaceuticals PLC 17 October 2007 Issued by Citigate Dewe Rogerson Ltd, Birmingham Date: Wednesday, 17 October 2007 Dechra(R) Pharmaceuticals PLC Interim Management Statement Dechra Pharmaceuticals PLC ('Dechra' or the 'Group'), which holds its Annual General Meeting today at 10.00 am, publishes its first Interim Management Statement as required by the UK Listing Authority Disclosure and Transparency Rules. The Group has started the financial year in line with management expectations; there have been no significant changes in its financial position or performance since the publication of the Annual Report in respect of the year ended 30 June 2007 and the financial position of the Group remains strong. The Pharmaceuticals Division has continued its strong growth with revenue for the first quarter of the financial year ahead of the same period last year. The Group's US operation is achieving encouraging revenues from the Pharmaderm products acquired in May and is now trading profitably. The Services Division continues to take advantage of strong market conditions, with market share at National Veterinary Services remaining above 44%. There have been no material events or transactions between 1 July 2007 and the date of this announcement. The Board remains confident that the Group will continue to make good strategic progress in line with management expectations throughout the remainder of the financial year. Enquiries: Ian Page, Chief Executive Fiona Tooley, Director Simon Evans, Group Finance Director Keith Gabriel, Senior Account Manager Dechra Pharmaceuticals PLC Citigate Dewe Rogerson Tel: 01782 771100 Tel: 0121 455 8370 Mobile: 07775 642222 (IP) or 07775 642220 (SE) Mobile: 07785 703523 (FMT) or 07770 788624 (KG) www.dechra.com corporate.enquiries@dechra.com Trade Marks appear throughout this release in italics. Dechra and the Dechra 'D' logo are registered Trade Marks of Dechra Pharmaceuticals PLC. This information is provided by RNS The company news service from the London Stock Exchange LID
UK 100

Latest directors dealings